NO2024009I1 - Gefapixant, or a pharmaceutically acceptable salt thereof - Google Patents
Gefapixant, or a pharmaceutically acceptable salt thereofInfo
- Publication number
- NO2024009I1 NO2024009I1 NO2024009C NO2024009C NO2024009I1 NO 2024009 I1 NO2024009 I1 NO 2024009I1 NO 2024009 C NO2024009 C NO 2024009C NO 2024009 C NO2024009 C NO 2024009C NO 2024009 I1 NO2024009 I1 NO 2024009I1
- Authority
- NO
- Norway
- Prior art keywords
- gefapixant
- pharmaceutically acceptable
- acceptable salt
- salt
- pharmaceutically
- Prior art date
Links
- HLWURFKMDLAKOD-UHFFFAOYSA-N 5-(2,4-diaminopyrimidin-5-yl)oxy-2-methoxy-4-propan-2-ylbenzenesulfonamide Chemical compound C1=C(S(N)(=O)=O)C(OC)=CC(C(C)C)=C1OC1=CN=C(N)N=C1N HLWURFKMDLAKOD-UHFFFAOYSA-N 0.000 title 1
- 229940121285 gefapixant Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562234584P | 2015-09-29 | 2015-09-29 | |
US201662336381P | 2016-05-13 | 2016-05-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO2024009I1 true NO2024009I1 (no) | 2024-03-06 |
Family
ID=58424436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO2024009C NO2024009I1 (no) | 2015-09-29 | 2024-03-06 | Gefapixant, or a pharmaceutically acceptable salt thereof |
Country Status (22)
Country | Link |
---|---|
US (3) | US11260056B2 (no) |
EP (2) | EP3355889B1 (no) |
JP (1) | JP6877441B2 (no) |
KR (1) | KR20180054843A (no) |
AU (1) | AU2016330466B2 (no) |
CA (1) | CA2998742C (no) |
CY (2) | CY1125963T1 (no) |
DK (1) | DK3355889T3 (no) |
ES (1) | ES2942711T3 (no) |
FI (2) | FI3355889T3 (no) |
FR (1) | FR24C1010I2 (no) |
HR (1) | HRP20230445T1 (no) |
HU (2) | HUE061764T2 (no) |
LT (1) | LT3355889T (no) |
MX (1) | MX390084B (no) |
NL (1) | NL301260I2 (no) |
NO (1) | NO2024009I1 (no) |
PL (1) | PL3355889T3 (no) |
PT (1) | PT3355889T (no) |
RS (1) | RS64155B1 (no) |
SI (1) | SI3355889T1 (no) |
WO (1) | WO2017058645A1 (no) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220148928A (ko) | 2016-12-20 | 2022-11-07 | 애퍼런트 파마슈티컬스 인크. | P2x3 길항제의 결정질 염 및 다형체 |
US10111883B1 (en) * | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
KR20210009341A (ko) * | 2018-05-15 | 2021-01-26 | 바이엘 악티엔게젤샤프트 | 신경 섬유 감작과 연관된 질환의 치료를 위한 1,3-티아졸-2-일 치환된 벤즈아미드 |
US11883407B2 (en) * | 2018-10-05 | 2024-01-30 | Shionogi & Co., Ltd. | Medicament for the treatment of chronic cough |
CA3138780A1 (en) * | 2019-04-30 | 2020-11-05 | Beijing Tide Pharmaceutical Co., Ltd. | Method for treating cough by using diaminopyrimidine compound |
AU2020281923A1 (en) | 2019-05-31 | 2022-01-06 | Chiesi Farmaceutici S.P.A. | Amino quinazoline derivatives as P2X3 inhibitors |
JP2022534434A (ja) | 2019-05-31 | 2022-07-29 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | P2x3阻害剤としてのピリドピリミジン誘導体 |
EP4032884A4 (en) | 2019-09-19 | 2023-09-13 | Shionogi & Co., Ltd. | 1,3,5-TRIAZINE DERIVATIVE CRYSTAL OR SOLVATE THEREOF AND PRODUCTION METHOD THEREFOR |
CN111635368B (zh) * | 2020-06-12 | 2021-06-29 | 东莞市东阳光仿制药研发有限公司 | 一种胺化合物的制备方法 |
MX2023005805A (es) | 2020-11-27 | 2023-06-01 | Chiesi Farm Spa | Derivados de 4-aminas de (aza)quinolina como inhibidores del purinorreceptor 3 p2x (p2x3). |
JP2023550831A (ja) | 2020-11-27 | 2023-12-05 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | P2x3阻害剤としてのフタラジン誘導体 |
KR20230113309A (ko) | 2020-11-27 | 2023-07-28 | 키에시 파르마슈티시 엣스. 피. 에이. | P2x3 억제제로서 아미노 퀴나졸린 유도체 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1725540T3 (pl) | 2004-03-05 | 2013-02-28 | Hoffmann La Roche | Diaminopirymidyny jako antagoniści p2x3 i p2x2/3 |
EP1773405A4 (en) | 2004-07-22 | 2011-10-05 | Duska Scient Co | METHOD FOR DIAGNOSIS, MONITORING AND TREATMENT OF LUNG DISEASES |
WO2007025899A1 (en) | 2005-09-01 | 2007-03-08 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
ES2562056T3 (es) | 2005-09-01 | 2016-03-02 | F. Hoffmann-La Roche Ag | Diaminopirimidinas como moduladores P2X3 y P2X2/3 |
JP4850914B2 (ja) * | 2005-09-01 | 2012-01-11 | エフ.ホフマン−ラ ロシュ アーゲー | P2x3およびp2x2/3モジュレーターとしてのジアミノピリミジン |
JP4820873B2 (ja) | 2005-09-01 | 2011-11-24 | エフ.ホフマン−ラ ロシュ アーゲー | アリールオキシジアミノピリミジンの合成方法 |
KR101176701B1 (ko) * | 2006-10-04 | 2012-08-23 | 에프. 호프만-라 로슈 아게 | 펜옥시 다이아미노피리미딘 유도체의 합성 방법 |
WO2008104474A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Diaminopyrimidines |
US9284279B2 (en) * | 2013-08-23 | 2016-03-15 | Afferent Pharmaceuticals, Inc. | Substituted pyrimidines for treatment of acute cough, chronic cough and urge to cough |
-
2016
- 2016-09-23 US US15/764,174 patent/US11260056B2/en active Active
- 2016-09-23 PL PL16852340.5T patent/PL3355889T3/pl unknown
- 2016-09-23 SI SI201631686T patent/SI3355889T1/sl unknown
- 2016-09-23 MX MX2018003893A patent/MX390084B/es unknown
- 2016-09-23 FI FIEP16852340.5T patent/FI3355889T3/fi active
- 2016-09-23 DK DK16852340.5T patent/DK3355889T3/da active
- 2016-09-23 AU AU2016330466A patent/AU2016330466B2/en active Active
- 2016-09-23 RS RS20230321A patent/RS64155B1/sr unknown
- 2016-09-23 JP JP2018535821A patent/JP6877441B2/ja active Active
- 2016-09-23 HU HUE16852340A patent/HUE061764T2/hu unknown
- 2016-09-23 EP EP16852340.5A patent/EP3355889B1/en active Active
- 2016-09-23 LT LTEPPCT/US2016/053223T patent/LT3355889T/lt unknown
- 2016-09-23 WO PCT/US2016/053223 patent/WO2017058645A1/en active Application Filing
- 2016-09-23 ES ES16852340T patent/ES2942711T3/es active Active
- 2016-09-23 KR KR1020187011747A patent/KR20180054843A/ko not_active Ceased
- 2016-09-23 EP EP23155536.8A patent/EP4215182A1/en active Pending
- 2016-09-23 CA CA2998742A patent/CA2998742C/en active Active
- 2016-09-23 PT PT168523405T patent/PT3355889T/pt unknown
- 2016-09-23 HR HRP20230445TT patent/HRP20230445T1/hr unknown
-
2022
- 2022-01-24 US US17/582,485 patent/US20220143015A1/en not_active Abandoned
-
2023
- 2023-05-09 CY CY20231100217T patent/CY1125963T1/el unknown
-
2024
- 2024-03-04 NL NL301260C patent/NL301260I2/nl unknown
- 2024-03-05 HU HUS2400004C patent/HUS2400004I1/hu unknown
- 2024-03-06 NO NO2024009C patent/NO2024009I1/no unknown
- 2024-03-12 FR FR24C1010C patent/FR24C1010I2/fr active Active
- 2024-03-13 FI FIC20240006C patent/FIC20240006I1/fi unknown
- 2024-03-13 CY CY2024005C patent/CY2024005I1/el unknown
- 2024-04-19 US US18/640,100 patent/US20240285620A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO2021035I1 (no) | Risdiplam or a pharmaceutically acceptable salt thereof | |
NL301286I2 (nl) | Danicopan, of een farmaceutisch aanvaardbaar zout ervan | |
NO2024001I1 (no) | Ritlecitinib, or a pharmaceutically acceptable salt thereof | |
NO2022059I1 (no) | Lenacapavir or a pharmaceutically acceptable salt thereof, in particular lenacapavir sodium | |
NO2022004I1 (no) | abrocitinib, or a pharmaceutically acceptable salt thereof | |
NO2024042I1 (no) | Iptacopan or a pharmaceutically acceptable salt thereof | |
NO2023043I1 (no) | Mavacamten or a pharmaceutically acceptable salt thereof | |
NL301111I2 (nl) | Entrectinib of een farmaceutisch aanvaardbaar zout daarvan | |
NO2022005I1 (no) | Zanubrutinib or a pharmaceutically acceptable salt thereof | |
NO2024009I1 (no) | Gefapixant, or a pharmaceutically acceptable salt thereof | |
NO2022009I1 (no) | Lumasiran, optionally in the form of a salt | |
NL301217I2 (nl) | tirzepatide en farmaceutisch aanvaardbare zouten daarvan | |
NO2024007I1 (no) | Elacestrant or a salt thereof | |
NO2022058I1 (no) | Capmatinib or a pharmaceutically acceptable salt thereof | |
FIC20240025I1 (fi) | Momelotinibi, mukaanlukien momelotinibidihydrokloridimonohydraatti | |
LT3230281T (lt) | 1,3-tiazol-2-ilu pakeisti benzamidai | |
LT3188717T (lt) | Vaisto forma, apimanti daleles | |
DK3253762T3 (da) | 9h-pyrrolo-dipyridinderivater. | |
BR112017027227A2 (pt) | Agente anti-câncer | |
IL255823A (en) | Urea derivative or pharmacologically acceptable salt thereof | |
BR112017014839A2 (pt) | novos microbicidas | |
LT3371168T (lt) | Indolin-2-ono dariniai | |
DK3445742T3 (da) | Krystallin tapentadolphosphat | |
NO2024058I1 (no) | delgocitinib or a pharmaceutically acceptable salt thereof | |
ZA201708611B (en) | Pyrazole derivative, or pharmaceutically acceptable salt thereof |